Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.

Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, Tsuyama N, Ishikawa Y, Hatake K.

Jpn J Clin Oncol. 2012 Aug;42(8):697-703. doi: 10.1093/jjco/hys085.

2.

Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.

Okuma HS, Iwasa S, Shoji H, Takashima A, Okita N, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y.

Anticancer Res. 2014 Sep;34(9):5037-41.

PMID:
25202088
3.

A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).

Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, Sekine I, Watanabe S, Yoshimura M, Yamamoto N, Oshita F, Kubota K, Nagai K.

Lung Cancer. 2014 Jun;84(3):254-8. doi: 10.1016/j.lungcan.2014.03.007.

PMID:
24679951
4.

Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.

Lu ZH, Li J, Lu M, Zhang XT, Li J, Zhou J, Wang XC, Gong JF, Gao J, Li Y, Shen L.

Med Oncol. 2013;30(3):664. doi: 10.1007/s12032-013-0664-y.

PMID:
23864251
5.

Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.

Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H, Nagai K.

J Thorac Oncol. 2013 Jul;8(7):980-4. doi: 10.1097/JTO.0b013e31828f6989.

6.

Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.

Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N.

Jpn J Clin Oncol. 2010 Apr;40(4):313-8. doi: 10.1093/jjco/hyp173.

7.

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.

Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, Hamaguchi T, Yamada Y, Shimada Y, Taniguchi H, Shirao K.

Gastric Cancer. 2011 Jun;14(2):161-5. doi: 10.1007/s10120-011-0025-5.

PMID:
21327441
8.

First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma.

Du Z, Wang Y, Zhou Y, Wen F, Li Q.

Tumori. 2013 Jan-Feb;99(1):57-60. doi: 10.1700/1248.13789.

PMID:
23549001
9.

Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.

Bajetta E, Catena L, Biondani P, Pusceddu S, Valente M, Bianco N, Novelli E.

Anticancer Res. 2014 Oct;34(10):5657-60.

PMID:
25275070
10.

A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).

Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, Watanabe S, Yamamoto N, Tamura T, Asamura H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group.; Lung Cancer Study Group of the Japan Clinical Oncology Group..

Jpn J Clin Oncol. 2014 Apr;44(4):379-82. doi: 10.1093/jjco/hyt233.

11.

Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.

Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N, Nokihara H, Yamada K, Tamura T.

Jpn J Clin Oncol. 2007 Jul;37(7):482-6.

12.

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.

Dig Dis Sci. 2006 Jun;51(6):1033-8.

PMID:
16865563
13.

Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.

Kim HG, Lee GW, Kang JH, Kang MH, Hwang IG, Kim SH, Hahm JR, Jeong YY, Kim HC, Lee JD, Lee JS, Hwang YS.

Lung Cancer. 2008 Aug;61(2):220-6. doi: 10.1016/j.lungcan.2007.12.020.

PMID:
18272249
14.

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T.

Cancer Sci. 2014 Sep;105(9):1176-81. doi: 10.1111/cas.12473.

15.

Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.

Lee JE, Park HS, Jung SS, Kim JO, Kim SY.

Oncology. 2007;73(1-2):76-80. doi: 10.1159/000120632.

PMID:
18334853
16.

[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].

Yamashita K, Ishikawa D, Nanjo S, Takeuchi S, Yamada T, Mouri H, Ohtsubo K, Yasumoto K, Kumagai M, Ueda Y, Yano S.

Gan To Kagaku Ryoho. 2012 Sep;39(9):1427-30. Japanese.

PMID:
22996784
17.
18.

Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M.

Lung Cancer. 2011 Dec;74(3):492-6. doi: 10.1016/j.lungcan.2011.05.013.

PMID:
21665316
19.

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V.

Gynecol Oncol. 2003 Jun;89(3):402-7.

PMID:
12798702
20.

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.

Takahari D, Shimada Y, Takeshita S, Nishitani H, Takashima A, Okita N, Hirashima Y, Kato K, Hamaguchi T, Yamada Y, Shirao K.

Gastric Cancer. 2010 Aug;13(3):186-90. doi: 10.1007/s10120-010-0557-0.

PMID:
20820988
Items per page

Supplemental Content

Support Center